Deborah Vallee
Overview
Explore the profile of Deborah Vallee including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
412
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vallee D, Blanc M, Lebeaupin C, Bailly-Maitre B
Med Sci (Paris)
. 2020 Mar;
36(2):119-129.
PMID: 32129747
The incidence of chronic liver disease is constantly increasing, owing to the obesity epidemic. Non-alcoholic fatty liver disease (NAFLD) is currently affecting 20-30% of the general population and 75-100% of...
2.
Lebeaupin C, Blanc M, Vallee D, Keller H, Bailly-Maitre B
FEBS J
. 2019 Dec;
287(9):1722-1736.
PMID: 31841271
Cellular gatekeepers are essential to maintain order within a cell and anticipate signals of stress to promote survival. BCL2 associated X, apoptosis regulator (BAX) inhibitor-1 (BI-1), also named transmembrane BAX...
3.
Bussiere R, Oules B, Mary A, Vaillant-Beuchot L, Martin C, El Manaa W, et al.
Cells
. 2019 Dec;
8(12).
PMID: 31795302
Dysregulation of the Endoplasmic Reticulum (ER) Ca homeostasis and subsequent ER stress activation occur in Alzheimer Disease (AD). We studied the contribution of the human truncated isoform of the sarco-endoplasmic...
4.
Lebeaupin C, Vallee D, Hazari Y, Hetz C, Chevet E, Bailly-Maitre B
J Hepatol
. 2018 Jun;
69(4):927-947.
PMID: 29940269
The global epidemic of obesity has been accompanied by a rising burden of non-alcoholic fatty liver disease (NAFLD), with manifestations ranging from simple steatosis to non-alcoholic steatohepatitis, potentially developing into...
5.
Lebeaupin C, Vallee D, Rousseau D, Patouraux S, Bonnafous S, Adam G, et al.
Hepatology
. 2018 Feb;
68(2):515-532.
PMID: 29457838
Conclusion: Targeting IRE1α-dependent NLRP3 inflammasome signaling with pharmacological agents or by BI-1 may represent a tangible therapeutic strategy for NASH. (Hepatology 2018).